ArticleChemical biology & drug design2026
Polycationic Peptides That Bind T-Box Riboswitch Antiterminator RNA and Inhibit Riboswitch Function.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Resistance to antibiotic treatments continues to be a significant health challenge and necessitates investigating novel antibacterial targets including noncoding regulatory RNA. The antiterminator RNA element of the T-box riboswitch is one such novel target. In this report, we investigated a spatially dispersed polycationic pharmacophore model for targeting the T-box antiterminator RNA. Decapeptides were designed based on a known alkyl polyamine agonist of the T-box riboswitch. Antiterminator model RNA binding was assessed using native mass spectrometry and modulation of T-box riboswitch function determined using a previously validated fluorescence-based assay. One peptide was identified that formed a complex with antiterminator model RNA and selectively inhibited T-box riboswitch transcription readthrough (both with and without tRNA induction). The inhibitory activity of this polycationic peptide, which was designed to mimic biogenic polyamines, has implications for future drug discovery efforts targeting the T-box riboswitch and other medicinally important noncoding regulatory RNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.